Search

Your search keyword '"Blasi, Livio"' showing total 148 results
Start Over Author "Blasi, Livio"
148 results on '"Blasi, Livio"'

1. Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study

Author

Iacovino, Maria Lucia, Celant, Simone, Tomassini, Luca, Arenare, Laura, Caglio, Andrea, Canciello, Andrea, Salerno, Flavio, Olimpieri, Pier Paolo, Di Segni, Susanna, Sferrazza, Antonella, Piccirillo, Maria Carmela, Beretta, Giordano Domenico, Pinto, Carmine, Blasi, Livio, Cinieri, Saverio, Cavanna, Luigi, Di Maio, Massimo, Russo, Pierluigi, and Perrone, Francesco

Published
2024
Full Text
View/download PDF

2. The use of liquid biopsy comprehensive genomic profiling to identify the molecular landscape of patients with metastatic colorectal cancer who are candidates for anti-EGFR rechallange therapy: Findings from the CAVE-2 GOIM trial.

Author

Napolitano, Stefania, Boscolo Bielo, Luca, Martini, Giulia, Pietrantonio, Filippo, Pisconti, Salvatore, Sartore-Bianchi, Andrea, Blasi, Livio, Tortora, Giampaolo, Zaniboni, Alberto, Pinto, Carmine, Santabarbara, Giuseppe, Avallone, Antonio, Leo, Silvana, Lotesoriere, Claudio, Latiano, Tiziana, Zampino, M. Giulia, Martinelli, Erika, Troiani, Teresa, Ciardiello, Fortunato, and Ciardiello, Davide

Published
2025
Full Text
View/download PDF

3. Pain Assessment and Management in Oncological Practice: A Survey from the Italian Network of Supportive Care in Oncology.

Author

Antonuzzo, Andrea, Gonella, Silvia, Blasi, Livio, Carnio, Simona, Franzese, Ciro, Marano, Luigi, Santini, Daniele, and Bossi, Paolo

Abstract

Background/Objectives: Cancer pain is prevalent across all stages of the disease, significantly impacting patients' lives. Despite the availability of guidelines, its assessment and management remain suboptimal in many clinical settings. This study aimed to explore how healthcare professionals in Italy assess and manage cancer pain, identifying gaps and educational needs to improve adherence to best practices. Methods: A multidisciplinary Scientific Board designed an online survey comprising 28 items addressing demographics, pain assessment tools, perception of pain, pharmacological management, adverse effects, and barriers to care. The survey targeted oncologists, nurses, radiotherapists, and surgeons within the Italian Network of Supportive Care in Oncology. Data were collected from March to May 2024 and analyzed descriptively. Results: Eighty-five professionals participated, predominantly oncologists (63.5%). Most respondents utilized pain scales, with the Numerical Rating Scale (60.3%) being the most frequent. However, specific tools like the Edmonton Symptom Assessment System (ESAS) were underutilized, possibly due to limited training and time constraints. Factors influencing analgesic choice included patient comorbidities (30.3%) and polypharmacy (28.0%). The main barriers to effective pain management included inadequate training (85.5%) and poor communication between patients and caregivers (40.6%) and within care teams (31.9%). Preventive measures for opioid-induced adverse events were widely employed, with laxatives (52.7%) and antiemetics (40.5%) being the most common. Conclusions: Findings underscore the need for structured training programs, improved communication, and integration of validated assessment tools. A multidisciplinary, proactive approach to cancer pain assessment and management is essential to optimize care and reduce its burden across all disease stages. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

5. Virtual Multidisciplinary Tumor Boards: A Narrative Review Focused on Lung Cancer

Author

Gebbia, Vittorio, Guarini, Aurelia, Piazza, Dario, Bertani, Alessandro, Spada, Massimiliano, Verderame, Francesco, Sergi, Concetta, Potenza, Enrico, Fazio, Ivan, Blasi, Livio, La Sala, Alba, Mortillaro, Gianluca, Roz, Elena, Marchese, Roberto, Chiarenza, Maurizio, Soto-Parra, Hector, Valerio, Maria Rosaria, Agneta, Giuseppe, Amato, Carmela, Lipari, Helga, Baldari, Sergio, Ferraù, Francesco, Di Grazia, Alfio, Mancuso, Gianfranco, Rizzo, Sergio, and Firenze, Alberto

Published
2021
Full Text
View/download PDF

6. Management of patients with cancer during the COVID-19 pandemic: The Italian perspective on the second wave

Author

Indini, Alice, Pinotti, Graziella, Artioli, Fabrizio, Aschele, Carlo, Bernardi, Daniele, Butera, Alfredo, Defraia, Efisio, Fasola, Gianpiero, Gamucci, Teresa, Giordano, Monica, Iaria, Antonino, Leo, Silvana, Ribecco, Angela S., Rossetti, Riccardo, Savastano, Clementina, Schena, Marina, Silva, Rosa R., Grossi, Francesco, and Blasi, Livio

Published
2021
Full Text
View/download PDF

8. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Author

Falcone, Alfredo, Lonardi, Sara, De Braud, Filippo Guglielmo Maria, Bordonaro, Roberto, Maiello, Evaristo, Tamburini, Emiliano, Santini, Daniele, Frassineti, Giovanni Luca, Gamucci, Teresa, Aprile, Giuseppe, Zaniboni, Alberto, Granetto, Cristina, Buonadonna, Angela, Di Costanzo, Francesco, Tomasello, Gianluca, Gianni, Luca, Di Donato, Samantha, Carlomagno, Chiara, Clavarezza, Matteo, Racca, Patrizia, Mambrini, Andrea, Roselli, Mario, Allegrini, Giacomo, Sobrero, Alberto, Aglietta, Massimo, Corgna, Enrichetta, Cortesi, Enrico, Corsi, Domenico Cristiano, Ballestrero, Alberto, Bonetti, Andrea, Di Clemente, Francesco, Ruggeri, Enzo, Ciardiello, Fortunato, Benasso, Marco, Vitello, Stefano, Cinieri, Saverio, Mosconi, Stefania, Silvestris, Nicola, Frassoldati, Antonio, Cupini, Samantha, Bertolini, Alessandro, Tortora, Giampaolo, Bengala, Carmelo, Ferrari, Daris, Ardizzoia, Antonia, Milandri, Carlo, Chiara, Silvana, Romano, Gianpiero, Miraglia, Stefania, Scaltriti, Laura, Pucci, Francesca, Blasi, Livio, Brugnatelli, Silvia, Fioretto, Luisa, Ribecco, Angela Stefania, Longarini, Raffaella, Frisinghelli, Michela, Banzi, Maria, Cremolini, Chiara, Antoniotti, Carlotta, Rossini, Daniele, Loupakis, Fotios, Pietrantonio, Filippo, Latiano, Tiziana Pia, Passardi, Alessandro, Marmorino, Federica, Grande, Roberta, Murgioni, Sabina, Moretto, Roberto, Corallo, Salvatore, Cordio, Stefano, Antonuzzo, Lorenzo, Masi, Gianluca, Ronzoni, Monica, Ritorto, Giuliana, Cupini, Samanta, Mammoliti, Serafina, Fenocchio, Elisabetta, Zagonel, Vittorina, Fontanini, Gabriella, Ugolini, Clara, and Boni, Luca

Published
2020
Full Text
View/download PDF

9. Prostate-specific membrane antigen-PET/CT may result in stage migration in prostate cancer: performances, quantitative analysis, and potential criticism in the clinical practice

Author

Alongi, Pierpaolo, primary, Messina, Marco, additional, Pepe, Alessio, additional, Arnone, Annachiara, additional, Vultaggio, Viola, additional, Longo, Costanza, additional, Fiasconaro, Elisa, additional, Mirabile, Alessia, additional, Ricapito, Rosaria, additional, Blasi, Livio, additional, Arnone, Gaspare, additional, and Messina, Carlo, additional

Published
2024
Full Text
View/download PDF

10. Italian Nivolumab Expanded Access Program in Nonsquamous Non–Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients

Author

Garassino, Marina Chiara, Gelibter, Alain Jonathan, Grossi, Francesco, Chiari, Rita, Soto Parra, Hector, Cascinu, Stefano, Cognetti, Francesco, Turci, Daniele, Blasi, Livio, Bengala, Carmelo, Mini, Enrico, Baldini, Editta, Quadrini, Silvia, Ceresoli, Giovanni Luca, Antonelli, Paola, Vasile, Enrico, Pinto, Carmine, Fasola, Gianpiero, Galetta, Domenico, Macerelli, Marianna, Giannarelli, Diana, Lo Russo, Giuseppe, and de Marinis, Filippo

Published
2018
Full Text
View/download PDF

11. WITHDRAWN: Corrigendum to “Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study” [The Lancet Regional Health – Europe 41 (2024) 100912]

Author

Iacovino, Maria Lucia, Celant, Simone, Tomassini, Luca, Arenare, Laura, Caglio, Andrea, Canciello, Andrea, Salerno, Flavio, Olimpieri, Pier Paolo, Di Segni, Susanna, Sferrazza, Antonella, Piccirillo, Maria Carmela, Domenico Beretta, Giordano, Pinto, Carmine, Blasi, Livio, Cinieri, Saverio, Cavanna, Luigi, Di Maio, Massimo, Russo, Pierluigi, and Perrone, Francesco

Published
2024
Full Text
View/download PDF

12. Corrigendum to “Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study” [The Lancet Regional Health – Europe 41 (2024) 100912]

Author

Iacovino, Maria Lucia, Celant, Simone, Tomassini, Luca, Arenare, Laura, Caglio, Andrea, Canciello, Andrea, Salerno, Flavio, Olimpieri, Pier Paolo, Di Segni, Susanna, Sferrazza, Antonella, Piccirillo, Maria Carmela, Beretta, Giordano Domenico, Pinto, Carmine, Blasi, Livio, Cinieri, Saverio, Cavanna, Luigi, Di Maio, Massimo, Russo, Pierluigi, and Perrone, Francesco

Published
2024
Full Text
View/download PDF

13. Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study

Author

Cazzaniga, Marina Elena, primary, Pronzato, Paolo, additional, Amoroso, Domenico, additional, Bernardo, Antonio, additional, Biganzoli, Laura, additional, Bisagni, Giancarlo, additional, Blasi, Livio, additional, Bria, Emilio, additional, Cognetti, Francesco, additional, Crinò, Lucio, additional, De Laurentiis, Michelino, additional, Del Mastro, Lucia, additional, De Placido, Sabino, additional, Beano, Alessandra, additional, Ferraù, Francesco, additional, Foladore, Silva, additional, Forcignanò, Rosachiara, additional, Gamucci, Teresa, additional, Garrone, Ornella, additional, Gennari, Alessandra, additional, Giordano, Monica, additional, Giotta, Francesco, additional, Giovanardi, Filippo, additional, Latini, Luciano, additional, Livi, Lorenzo, additional, Marchetti, Paolo, additional, Mattioli, Rodolfo, additional, Michelotti, Andrea, additional, Montemurro, Filippo, additional, Putzu, Carlo, additional, Riccardi, Ferdinando, additional, Ricciardi, Giuseppina, additional, Romagnoli, Emanuela, additional, Sarobba, Giuseppina, additional, Spazzapan, Simon, additional, Tagliaferri, Pierosandro, additional, Tinari, Nicola, additional, Tonini, Giuseppe, additional, Turletti, Anna, additional, Verusio, Claudio, additional, Zambelli, Alberto, additional, and Mustacchi, Giorgio, additional

Published
2023
Full Text
View/download PDF

14. Preferred Imaging for Target Volume Delineation for Radiotherapy of Recurrent Glioblastoma: A Literature Review of the Available Evidence.

Author

Cuccia, Francesco, Jafari, Fatemeh, D'Alessandro, Salvatore, Carruba, Giuseppe, Craparo, Giuseppe, Tringali, Giovanni, Blasi, Livio, and Ferrera, Giuseppe

Subjects
RADIOTHERAPY, GLIOBLASTOMA multiforme, POSITRON emission tomography, OVERALL survival, CHI-squared test, RADIATION injuries
Abstract

Background: Recurrence in glioblastoma lacks a standardized treatment, prompting an exploration of re-irradiation's efficacy. Methods: A comprehensive systematic review from January 2005 to May 2023 assessed the role of MRI sequences in recurrent glioblastoma re-irradiation. The search criteria, employing MeSH terms, targeted English-language, peer-reviewed articles. The inclusion criteria comprised both retrospective and prospective studies, excluding certain types and populations for specificity. The PICO methodology guided data extraction, and the statistical analysis employed Chi-squared tests via MedCalc v22.009. Results: Out of the 355 identified studies, 81 met the criteria, involving 3280 patients across 65 retrospective and 16 prospective studies. The key findings indicate diverse treatment modalities, with linac-based photons predominating. The median age at re-irradiation was 54 years, and the median time interval between radiation courses was 15.5 months. Contrast-enhanced T1-weighted sequences were favored for target delineation, with PET-imaging used in fewer studies. Re-irradiation was generally well tolerated (median G3 adverse events: 3.5%). The clinical outcomes varied, with a median 1-year local control rate of 61% and a median overall survival of 11 months. No significant differences were noted in the G3 toxicity and clinical outcomes based on the MRI sequence preference or PET-based delineation. Conclusions: In the setting of recurrent glioblastoma, contrast-enhanced T1-weighted sequences were preferred for target delineation, allowing clinicians to deliver a safe and effective therapeutic option; amino acid PET imaging may represent a useful device to discriminate radionecrosis from recurrent disease. Future investigations, including the ongoing GLIAA, NOA-10, ARO 2013/1 trial, will aim to refine approaches and standardize methodologies for improved outcomes in recurrent glioblastoma re-irradiation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Fractionated Stereotactic Radiotherapy with Helical Tomotherapy for Brain Metastases: A Mono-Institutional Experience

Author

Cuccia, Francesco, primary, D’Alessandro, Salvatore, additional, Carruba, Giuseppe, additional, Figlia, Vanessa, additional, Spera, Antonio, additional, Cespuglio, Daniela, additional, Mortellaro, Gianluca, additional, Iacoviello, Giuseppina, additional, Lo Casto, Antonio, additional, Tringali, Giovanni, additional, Craparo, Giuseppe, additional, Blasi, Livio, additional, and Ferrera, Giuseppe, additional

Published
2023
Full Text
View/download PDF

18. Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study.

Author

Cazzaniga, Marina Elena, Pronzato, Paolo, Amoroso, Domenico, Bernardo, Antonio, Biganzoli, Laura, Bisagni, Giancarlo, Blasi, Livio, Bria, Emilio, Cognetti, Francesco, Crinò, Lucio, De Laurentiis, Michelino, Del Mastro, Lucia, De Placido, Sabino, Beano, Alessandra, Ferraù, Francesco, Foladore, Silva, Forcignanò, Rosachiara, Gamucci, Teresa, Garrone, Ornella, and Gennari, Alessandra

Subjects
CONFIDENCE intervals, ONCOGENES, METASTASIS, ANTINEOPLASTIC agents, HYDROCARBONS, TREATMENT effectiveness, DESCRIPTIVE statistics, RESEARCH funding, CELL lines, BEVACIZUMAB, ODDS ratio, PROGRESSION-free survival, BREAST tumors, LONGITUDINAL method, OVERALL survival, EVALUATION
Abstract

Simple Summary: Breast cancer is one of the most common oncological diseases among women in Western Countries and Italy as well. GIM 13-AMBRA is a patient journey study regarding how the prognosis of metastatic breast cancer patients has changed in the last decades as a result of the introduction of new drugs in clinical practice. This study also provides information regarding the different natural histories of breast cancer according to the presence or absence of hormone receptors and HER2 receptors. GIM 13-AMBRA is a longitudinal cohort study aimed at describing therapeutic strategies and the relative outcome parameters in 939 HER2-ve MBC patients. Taxanes–based regimens, or taxanes + targeted agents, mainly Bevacizumab, were the preferred first choice in both Luminal (30.2%) and TNBC (33.3%) patients. The median PFS1 was 12.5 months (95% CI 16.79–19.64), without any significant difference according to subtypes, while the median Time to first Treatment Change (TTC1) was significantly lower in TNBC patients (7.7 months—95% CI 5.7–9.2) in comparison to Luminal A (13.2 months, 95% CI 11.7–15.1) and Luminal B patients (11.8 months, 95% CI 10.3–12.8). PFS2 was significantly shorter in TNBC patients (5.5 months, 95% CI 4.3–6.5 vs. Luminal A—9.4, 95% CI 8.1–10.7, and Luminal B—7.7 95% CI 6.8–8.2, F-Ratio 4.30, p = 0.014). TTC2 was significantly lower in patients with TNBC than in those with the other two subtypes. The median OS1 was 35.2 months (95% CI 30.8–37.4) for Luminal A patients, which was significantly higher than that for both Luminal B (28.9 months, 95% CI 26.2–31.2) and TNBC (18.5 months, 95% CI 16–20.1, F-ratio 7.44, p = 0.0006). The GIM 13—AMBRA study is one of the largest collections ever published in Italy and provides useful results in terms of time outcomes for first, second, and further lines of treatment in HER2- MBC patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Breakthrough Cancer Pain: Preliminary Data of The Italian Oncologic Pain Multisetting Multicentric Survey (IOPS-MS)

Author

Mercadante, Sebastiano, Marchetti, Paolo, Cuomo, Arturo, Caraceni, Augusto, Mediati, Rocco Domenico, Mammucari, Massimo, Natoli, Silvia, Lazzari, Marzia, Dauri, Mario, Airoldi, Mario, Azzarello, Giuseppe, Bandera, Mauro, Blasi, Livio, Cartenì, Giacomo, Chiurazzi, Bruno, Costanzo, Benedetta Veruska Pierpaola, Degiovanni, Daniela, Fusco, Flavio, Guardamagna, Vittorio, Iaffaioli, Vincenzo, Liguori, Simeone, Lorusso, Vito, Mameli, Sergio, Mattioli, Rodolfo, Mazzei, Teresita, Melotti, Rita Maria, Menardo, Valentino, Miotti, Danilo, Moroso, Stefano, De Santis, Stefano, Orsetti, Remo, Papa, Alfonso, Ricci, Sergio, Sabato, Alessandro Fabrizio, Scelzi, Elvira, Sofia, Michele, Tonini, Giuseppe, Aielli, Federica, Valle, Alessandro, Caruselli, Amanda, Prestia, Giovanna, Giusti, Raffaele, Costanzi, Andrea, Angelini, Silvia, Iacono, Daniela, Mazzuca, Federica, Carnevale, Alessia, Bonome, Paolo, Nicosia, Luca, Scaringi, Claudia, Montalto, Adelaide, Russo, Gennaro, Forte, Cira Antonietta, Esposito, Gennaro, Bracchi, Paola, Zecca, Ernesto, Campa, Tiziana, Grecchi, Silvia, Pigni, Alessandra, Sammaro, Annunziata, Dodaro, Lucia, Ballerini, Giovanna, Vellucci, Renato, Caldarulo, Clarissa, Palombo, Elisa, Diviza, Marco, Gianfelice, Valentina, Silvestri, Claudia, Finocchi, Simona, Contu, Viviana, Fora, Gianluca, Pedani, Fulvia, Icardi, Massimiliano, Bellini, Elisa, Celano, Alfredo, Berardo, Roberto, Ostellino, Oliviero, Sartori, Kayta, Demartini, Paola, Scroccaro, Raffaella, Boscolo, Giorgia, Sartori, Donata, Rosetti, Francesco, Artioli, Grazia, Borgato, Lucia, Bertoldero, Giovanni, Veronese, Barbara, Vallini, Ilaria, Tuzi, Alessandro, Bolzacchini, Elena, Pinotti, Graziella, Alù, Massimiliano, Usset, Antonella, Arcuri, Carmela, Laudani, Agata, Pepe, Alessio, Scagliarini, Sarah, Sgarlata, Massimiliano Savio Maria, Raimondi, Massimo, Valenti, Salvatore Maria Giovanni, Bucceri, Alberto, Kasa, Alma, Budel, Paola, Caramellino, Anna, Ballarino, Paola, Donelli, Emanuela, Silvestro, Stefania, Tonetti, Rossella, Bozzoni, Samuela, Cocquio, Angela, Romano, Carmela, Nappi, Anna, Silvestro, Lucrezia, De Divitiis, Chiara, Ghidoni, Silvia, Cortinovis, Rosalba, Marchesi, Roberta, Fortis, Michele, Palermo, Loredana, Pisanu, Giovanni Maria, Carboni, Maura, Meloni, Francesca, Barillari, Daniele, Imperatori, Luca, Grilli, Gianni, Laici, Gianluca, Diacciati, Sara, Petreni, Paolo, Samolsky Dekel, Boaz, Marsigli, Federica, Manfreda, Miriam, Ghedini, Silvia, Bruno, Emanuela, Salvini, Emanuele, Gerboni, Davide, Saulle, Serena, Carella, Roberta, Pascoletti, Gaetano, Bolzonello, Silvia, Bonotto, Marta, Ellero, Silvia, Fasola, Gianpiero, Ongaro, Elena, Borghesi, Cristina, Germani, Lucia, De Ruvo, Edoardo, Marchetti, Federica, Pasquale, Milena, Masu, Lucia, Tammaro, Dario, Saracco, Elisabetta, Di Dato, Maria Teresa, Ferrara, Maurizio, Pironti, Andrea, Buonavolontà, Pietro, Ginocchi, Laura, Musettini, Gianna, Antonuzzo, Andrea, Caparello, Chiara, Lucchesi, Maurizio, Farnesi, Azzurra, Zampieri, Mari, Pisciotta, Manuela, Fioroni, Iacopo, Ratta, Raffaele, Cursano, Maria Concetta, Santini, Daniele, Potestà, Cinzia, Gallo, Gloria, Saber, Benhaz, and On behalf of the IOPS MS study group

Published
2017
Full Text
View/download PDF

22. Unmet Nutritional and Psychological Needs of Cancer Patients: An Integrated Multi-Professional Model Approach

Author

Carruba, Giuseppe, primary, Calagna, Maria Luisa, additional, Campisi, Ildegarda, additional, Cutrera, Stella, additional, Napoli, Laura, additional, Pitti, Giovanni, additional, Palmisano, Valentina, additional, Savio, Giuseppina, additional, Usset, Antonella, additional, Leonardi, Vita, additional, Di Pasquale, Angela, additional, Requirez, Salvatore, additional, and Blasi, Livio, additional

Published
2022
Full Text
View/download PDF

23. Erratum to: Breakthrough pain and its treatment: critical review and recommendations of IOPS (Italian Oncologic Pain Survey) expert group

Author

Mercadante, Sebastiano, Marchetti, Paolo, Cuomo, Arturo, Mammucari, Massimo, Caraceni, Augusto, Mediati, Rocco Domenico, Caruselli, Amanda, Costanzi, Andrea, Bracchi, Paola, Dodaro, Lucia, Contu, Viviana, Fora, Gianluca, Veronese, Barbara, Alu, Massimiliano, Chiurazzi, Bruno, Sgarlata, Massimiliano, Kasa, Alma, Donelli, Emanuela, Silvestro, Stefania, Romano, Carmela, Ghidoni, Silvia, Palermo, Loredana, Pisanu, Giovanni Maria, Imperatori, Luca, Diacciati, Sara, Samolsky Dekel, Boaz Gedaliahu, Bruno, Emanuela, Saulle, Serena, Bonotto, Marta, De santis, Stefano, Tammaro, Dario, Ginocchi, Laura, Zampieri, Mari, Fioroni, Iacopo, Gallo, Gloria, Saber, Benhaz, Dauri, Mario, Airoldi, Mario, Azzarello, Giuseppe, Bandera, Mauro, Blasi, Livio, Carteni, Giacomo, Costanzo, Veruska, Degiovanni, Daniela, Fusco, Flavio, Guardamagna, Vittorio, Iaffaioli, Vincenzo, Lazzari, Marzia, Liguori, Simeone, Lorusso, Vito, Mameli, Sergio, Mattioli, Rodolfo, Mazzei, Teresita, Melotti, Rita Maria, Menardo, Valentino, Miotti, Danilo, Moroso, Stefano, Natoli, Silvia, Orsetti, Remo, Papa, Alfonso, Ricci, Sergio, Sabato, Alessandro Fabrizio, Scelzi, Elvira, Sofia, Michele, Tonini, Giuseppe, Valle, Alessandro, and on behalf of the IOPS MS study Group

Published
2017
Full Text
View/download PDF

26. Italian results of the PRECONNECT study: safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancer

Author

Zaniboni, Alberto, primary, Barone, Carlo Antonio, additional, Banzi, Maria Chiara, additional, Bergamo, Francesca, additional, Blasi, Livio, additional, Bordonaro, Roberto, additional, Bartolomeo, Maria Di, additional, Costanzo, Francesco Di, additional, Frassineti, Giovanni Luca, additional, Garufi, Carlo, additional, Giuliani, Francesco, additional, Latiano, Tiziana Pia, additional, Martinelli, Erika, additional, Personeni, Nicola, additional, Racca, Patrizia, additional, Tamburini, Emiliano, additional, Tonini, Giuseppe, additional, Besse, Marie Georges, additional, Spione, Mario, additional, and Falcone, Alfredo, additional

Published
2021
Full Text
View/download PDF

27. Efficacy and Safety of the use of Pertuzumab in Metastatic Breast Cancer Patients in a Real-World Setting: Results from the SUPER-GONO (Gruppo Oncologico del Nord Ovest) Study

Author

Garrone, Ornella, primary, Giarratano, Tommaso, additional, Blondeaux, Eva, additional, D'Onofrio, Loretta, additional, Michelotti, Andrea, additional, Beano, Alessandra, additional, Aprile, Giuseppe, additional, Guarneri, Valentina, additional, Paccagnella, Matteo, additional, Vanella, Paola, additional, Saggia, Chiara, additional, Coltelli, Luigi, additional, Cazzaniga, Marina E, additional, Verde, Nicla La, additional, Ruatta, Fiorella, additional, Collovà, Elena, additional, Montemurro, Filippo, additional, Mastro, Lucia Del, additional, Landucci, Elisabetta, additional, Allegrini, Giacomo, additional, Santini, Daniele, additional, Blasi, Livio, additional, Ardito, Raffaele, additional, Denaro, Nerina, additional, DeConciliis, Enrico, additional, Airoldi, Mario, additional, and Merlano, Marco C, additional

Published
2021
Full Text
View/download PDF

28. Oxycodone/Acetaminophen: The Tailoring Combination Treatment for Specific Clinical Profile of Opioid Well-Responsive Cancer Pain

Author

De Santis, Stefano, primary, Simone, Maria Domenica, additional, Mercadante, Sebastiano, additional, Mediati, Rocco Domenico, additional, Vellucci, Renato, additional, Marchetti, Paolo, additional, Tonini, Giuseppe, additional, Cuomo, Arturo, additional, Caraceni, Augusto, additional, Natoli, Silvia, additional, Armento, Grazia, additional, Blasi, Livio, additional, and Mammucari, Massimo, additional

Published
2021
Full Text
View/download PDF

32. Breakthrough Cancer Pain Clinical Features and Differential Opioids Response: A Machine Learning Approach in Patients With Cancer From the IOPS-MS Study

Author

Pantano, Francesco, primary, Manca, Paolo, additional, Armento, Grazia, additional, Zeppola, Tea, additional, Onorato, Angelo, additional, Iuliani, Michele, additional, Simonetti, Sonia, additional, Vincenzi, Bruno, additional, Santini, Daniele, additional, Mercadante, Sebastiano, additional, Marchetti, Paolo, additional, Cuomo, Arturo, additional, Caraceni, Augusto, additional, Mediati, Rocco Domenico, additional, Vellucci, Renato, additional, Mammucari, Massimo, additional, Natoli, Silvia, additional, Lazzari, Marzia, additional, Dauri, Mario, additional, Adile, Claudio, additional, Airoldi, Mario, additional, Azzarello, Giuseppe, additional, Blasi, Livio, additional, Chiurazzi, Bruno, additional, Degiovanni, Daniela, additional, Fusco, Flavio, additional, Guardamagna, Vittorio, additional, Liguori, Simeone, additional, Palermo, Loredana, additional, Mameli, Sergio, additional, Masedu, Francesco, additional, Mazzei, Teresita, additional, Melotti, Rita Maria, additional, Menardo, Valentino, additional, Miotti, Danilo, additional, Moroso, Stefano, additional, Pascoletti, Gaetano, additional, De Santis, Stefano, additional, Orsetti, Remo, additional, Papa, Alfonso, additional, Ricci, Sergio, additional, Scelzi, Elvira, additional, Sofia, Michele, additional, Aielli, Federica, additional, Valle, Alessandro, additional, and Tonini, Giuseppe, additional

Published
2020
Full Text
View/download PDF

33. Metronomic oral vinorelbine in patients with advanced non-small cell lung cancer progressing after nivolumab immunotherapy: a retrospective analysis

Author

Gebbia, Vittorio, primary, Aiello, Marco Maria, additional, Banna, Giuseppe, additional, Blanco, Giusi, additional, Blasi, Livio, additional, Borsellino, Nicolò, additional, Giuffrida, Dariio, additional, Lo Mauro, Mario, additional, Mancuso, Gianfranco, additional, Piazza, Dario, additional, Savio, Giuseppina, additional, Soto Parra, Hector, additional, Valerio, Maria Rosaria, additional, Verderame, Francesco, additional, and Vigneri, Paolo, additional

Published
2020
Full Text
View/download PDF

34. Reactions and countermeasures of medical oncologists towards the incoming COVID-19 pandemic: a WhatsApp messenger-based report from the Italian College of Chief Medical Oncologists

Author

Blasi, Livio, primary, Bordonaro, Roberto, additional, Borsellino, Nicolò, additional, Butera, Alfredo, additional, Caruso, Michele, additional, Cordio, Stefano, additional, Liborio, Di Cristina, additional, Ferraù, Francesco, additional, Giuffrida, Dario, additional, Soto Parra, Hector, additional, Spada, Massimiliano, additional, Tralongo, Paolo, additional, Valenza, Roberto, additional, Verderame, Francesco, additional, Vitello, Stefano, additional, Zerilli, Filippo, additional, Piazza, Dario, additional, Firenze, Alberto, additional, and Gebbia, Vittorio, additional

Published
2020
Full Text
View/download PDF

35. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Author

Cremolini, Chiara, primary, Antoniotti, Carlotta, additional, Rossini, Daniele, additional, Lonardi, Sara, additional, Loupakis, Fotios, additional, Pietrantonio, Filippo, additional, Bordonaro, Roberto, additional, Latiano, Tiziana Pia, additional, Tamburini, Emiliano, additional, Santini, Daniele, additional, Passardi, Alessandro, additional, Marmorino, Federica, additional, Grande, Roberta, additional, Aprile, Giuseppe, additional, Zaniboni, Alberto, additional, Murgioni, Sabina, additional, Granetto, Cristina, additional, Buonadonna, Angela, additional, Moretto, Roberto, additional, Corallo, Salvatore, additional, Cordio, Stefano, additional, Antonuzzo, Lorenzo, additional, Tomasello, Gianluca, additional, Masi, Gianluca, additional, Ronzoni, Monica, additional, Di Donato, Samantha, additional, Carlomagno, Chiara, additional, Clavarezza, Matteo, additional, Ritorto, Giuliana, additional, Mambrini, Andrea, additional, Roselli, Mario, additional, Cupini, Samanta, additional, Mammoliti, Serafina, additional, Fenocchio, Elisabetta, additional, Corgna, Enrichetta, additional, Zagonel, Vittorina, additional, Fontanini, Gabriella, additional, Ugolini, Clara, additional, Boni, Luca, additional, Falcone, Alfredo, additional, De Braud, Filippo Guglielmo Maria, additional, Maiello, Evaristo, additional, Frassineti, Giovanni Luca, additional, Gamucci, Teresa, additional, Di Costanzo, Francesco, additional, Gianni, Luca, additional, Racca, Patrizia, additional, Allegrini, Giacomo, additional, Sobrero, Alberto, additional, Aglietta, Massimo, additional, Cortesi, Enrico, additional, Corsi, Domenico Cristiano, additional, Ballestrero, Alberto, additional, Bonetti, Andrea, additional, Di Clemente, Francesco, additional, Ruggeri, Enzo, additional, Ciardiello, Fortunato, additional, Benasso, Marco, additional, Vitello, Stefano, additional, Cinieri, Saverio, additional, Mosconi, Stefania, additional, Silvestris, Nicola, additional, Frassoldati, Antonio, additional, Cupini, Samantha, additional, Bertolini, Alessandro, additional, Tortora, Giampaolo, additional, Bengala, Carmelo, additional, Ferrari, Daris, additional, Ardizzoia, Antonia, additional, Milandri, Carlo, additional, Chiara, Silvana, additional, Romano, Gianpiero, additional, Miraglia, Stefania, additional, Scaltriti, Laura, additional, Pucci, Francesca, additional, Blasi, Livio, additional, Brugnatelli, Silvia, additional, Fioretto, Luisa, additional, Ribecco, Angela Stefania, additional, Longarini, Raffaella, additional, Frisinghelli, Michela, additional, and Banzi, Maria, additional

Published
2020
Full Text
View/download PDF

37. TAM895755_Supplementary_material_CLN – Supplemental material for Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study

Author

Adamo, Vincenzo, Ricciardi, Giuseppina Rosaria Rita, Giuffrida, Dario, Scandurra, Giuseppa, Russo, Antonio, Blasi, Livio, Spadaro, Pietro, Iacono, Carmelo, Parra, Hector J. Soto, Savarino, Antonino, Ferraú, Francesco, Zerilli, Filippo, Verderame, Francesco, Butera, Alfredo, Santangelo, Carlo, Franchina, Veronica, and Caruso, Michele

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, TAM895755_Supplementary_material_CLN for Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study by Vincenzo Adamo, Giuseppina Rosaria Rita Ricciardi, Dario Giuffrida, Giuseppa Scandurra, Antonio Russo, Livio Blasi, Pietro Spadaro, Carmelo Iacono, Hector J. Soto Parra, Antonino Savarino, Francesco Ferraú, Filippo Zerilli, Francesco Verderame, Alfredo Butera, Carlo Santangelo, Veronica Franchina and Michele Caruso in Therapeutic Advances in Medical Oncology

Published
2019
Full Text
View/download PDF

38. A Case Report of Adult Pineoblastoma Occurring in a Pregnant Woman

Author

CUCCIA, FRANCESCO, primary, MORTELLARO, GIANLUCA, additional, CESPUGLIO, DANIELA, additional, VALENTI, VITO, additional, DE GREGORIO, GIORGIA, additional, QUARTUCCIO, EMANUELE, additional, BLASI, LIVIO, additional, FRANCAVIGLIA, NATALE, additional, GALLO, CRISTINA, additional, LO CASTO, ANTONIO, additional, and FERRERA, GIUSEPPE, additional

Published
2019
Full Text
View/download PDF

39. Correction: Everolimus (Eve) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study (Oncotarget (2018) 9:77 (34639-34640) DOI: 10.18632/oncotarget.25874)

Author

Cazzaniga, Marina, Verusio, Claudio, Ciccarese, Mariangela, Fumagalli, Alberto, Sartori, Donata, Ancona, Chiara, Airoldi, Mario, Moretti, Gabriella, Ficorella, Corrado, Arcangeli, Valentina, Diodati, Lucrezia, Zambelli, Alberto, Febbraro, Antonio, Generali, Daniele, Pistelli, Mirco, Garrone, Ornella, Musolino, Antonino, Vici, Patrizia, Maur, Michela, Mentuccia, Lucia, La Verde, Nicla, Bianchi, Giulia, Artale, Salvatore, Blasi, Livio, Piezzo, Michela, Atzori, Francesco, Turletti, Anna, Benedetto, Chiara, Cursano, Maria Concetta, Fabi, Alessandra, Gebbia, Vittorio, Schirone, Antonio, Palumbo, Raffaella, Ferzi, Antonella, Frassoldati, Antonio, Scavelli, Claudio, and Clivio, Luca

Subjects
Oncology
Published
2018

40. Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study

Author

Cazzaniga, Marina, Verusio, Claudio, Ciccarese, Mariangela, Fumagalli, Alberto, Sartori, Donata, Valerio, Maria Rosaria, Airoldi, Mario, Moretti, Gabriella, Ficorella, Corrado, Arcangeli, Valentina, Diodati, Lucrezia, Zambelli, Alberto, Febbraro, Antonio, Generali, Daniele, Pistelli, Mirco, Garrone, Ornella, Musolino, Antonino, Vici, Patrizia, Maur, Michela, Mentuccia, Lucia, La Verde, Nicla, Bianchi, Giulia, Artale, Salvatore, Blasi, Livio, Piezzo, Michela, Atzori, Francesco, Turletti, Anna, Benedetto, Chiara, Cursano, Maria Concetta, Fabi, Alessandra, Gebbia, Vittorio, Schirone, Alessio, Palumbo, Raffaella, Ferzi, Antonella, Frassoldati, Antonio, Scavelli, Claudio, Clivio, Luca, and Torri, Valter

Subjects
Oncology, Correction
Abstract

The present analysis focuses on real-world data of Everolimus-Exemestane in advanced HR+ve, HER2-ve elderly breast cancer patients (aged 65 years) included in the EVA study, with unique findings in those aged 70 years.Data are collected from clinical records and analysed according to age cut-off (65 years; 65 - 69 years and {greater than or equal to} 70 years). Relationship of analyzed variables with response were tested by mean of a Mantel-Haenszel chi square test. Time to event analysis was described by Kaplan Meier approach and association with baseline characteristics was analysed by stratified log-rank test and proportional hazard model.From July 2013 to December 2015, the EVA study enrolled overall 404 pts. 154 patients out of 404 (38,1%) were aged {greater than or equal to} 65 years, of whom 87 were {greater than or equal to} 70 years. Median duration of EVE treatment was 28.5 weeks (95% CI 19.0 - 33.8) in patients aged 65-69 years and 24,4 weeks (95% CI 19,2 - 33,2) in those aged {greater than or equal to} 70 years. Fewer patients aged 65 years received the highest EVE Dose-Intensity (7.5 mg/day) in comparison to younger patients (49,6% vs. 66,8%). Grade 3-4 toxicities occurred to 55 patients (35,7%), mainly stomatitis (10,9%), rash (5,8%) and non-infectious pneumonitis (NIP) (3,6%). Some toxicities, such as weight loss and anaemia were peculiarly observed in patients aged {greater than or equal to} 70 years. Five treatment-related deaths were collected (3,2%).EVE-EXE combination remains one of the potential treatments in HR+ patients also for elderly ones.

Published
2018
Full Text
View/download PDF

41. Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study

Author

Adamo, Vincenzo, primary, Ricciardi, Giuseppina Rosaria Rita, additional, Giuffrida, Dario, additional, Scandurra, Giuseppa, additional, Russo, Antonio, additional, Blasi, Livio, additional, Spadaro, Pietro, additional, Iacono, Carmelo, additional, Soto Parra, Hector J., additional, Savarino, Antonino, additional, Ferraú, Francesco, additional, Zerilli, Filippo, additional, Verderame, Francesco, additional, Butera, Alfredo, additional, Santangelo, Carlo, additional, Franchina, Veronica, additional, and Caruso, Michele, additional

Published
2019
Full Text
View/download PDF

42. Is burnout affecting life satisfaction in oncologists? The moderating role of family concerns in an Italian sample.

Author

Cheli, Simone, Zagonel, Vittorina, Oliani, Cristina, Blasi, Livio, and Fioretto, Luisa

Subjects
FAMILY roles, PSYCHOLOGICAL burnout, JOB satisfaction, MEDICAL personnel, SATISFACTION, FAMILIES, DISEASE prevalence, EMOTIONS
Abstract

Objective: Burnout may represent a significant source of distress in health care professionals. Many studies have reported its negative effect on career satisfaction and personal life. The aim of the present study was to investigate the relation between burnout and life satisfaction in a large sample of Italian oncologists.Methods: An online survey was conducted of 14.5% of the Italian oncologists' population (n = 533) using Copenhagen Burnout Inventory, Satisfaction with Life Scale and additional questions exploring professional and personal factors. Moderated regression analysis was carried out to explore how burnout may relate to life satisfaction.Results: One out of 10 (10.5%) oncologists showed significant burnout symptoms, whereas 1 out of 3 (33.8%) reported being at least slightly dissatisfied with their own life. Family concerns significantly moderated the relationship between burnout and life satisfaction. Men and chiefs of cancer units or departments showed lower rates of burnout and life dissatisfaction than women and other oncologists, respectively.Conclusions: Reported results are in line with existing data about a limited burnout prevalence in Italian oncologists. We discuss the potential role of gender inequality in explaining our findings. The present study suggests that family concerns may be considered a risk factor for both burnout and life dissatisfaction in oncologists. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

43. Oxycodone/Acetaminophen: The Tailoring Combination Treatment for Specific Clinical Profile of Opioid Well-Responsive Cancer Pain.

Author

Santis, Stefano De, Simone, Maria Domenica, Mercadante, Sebastiano, Mediati, Rocco Domenico, Vellucci, Renato, Marchetti, Paolo, Tonini, Giuseppe, Cuomo, Arturo, Caraceni, Augusto, Natoli, Silvia, Armento, Grazia, Blasi, Livio, and Mammucari, Massimo

Subjects
CANCER pain, KARNOFSKY Performance Status, OXYCODONE, PAIN measurement, PAIN management, ACETAMINOPHEN
Abstract

Background: International guidelines recommend moderate-to-severe cancer pain to be treated with strong opioids. However, pain management remains an unsolved matter, at least in the demanding oncology and palliative care setting. Although cancer pain consists of multiple components, which interact in complex ways where combination therapy can better intercept multiple pain characteristics, few studies have used a non-opioid/opioid association to exploit possible synergistic actions. Even the efforts of a recent approach emphasizing appropriate pain assessment and accurate classification to obtain personalized pain management have not produced a satisfactory analgesic strategy. Objective: This analysis was intended to evaluate the effectiveness of the immediate release fixed combination of oxycodone/acetaminophen (OxyIR/Par) for the treatment of moderate-to-severe intensity background pain used alone or in combination with other strong opioids in cancer patients with breakthrough cancer pain (BTcP). This is a secondary analysis of a wider observational, prospective, multicenter study [Italian Oncologic Pain multiSetting Multicentric Survey (IOPS-MS)] performed on 179 patients treated with opioids for cancer pain who received the fixed combination of oxycodone/acetaminophen (OxyIR/Par) for the treatment of background pain (BGP). Results: Cancer patients with breakthrough cancer pain and controlled BGP (Background Pain) were classified according to the presence of analgesic therapy with tablets of fixed combination OxyIR/Par alone (group A, n=120) or tablets of fixed combination OxyIR/Par combined with other strong opioids (group B, n=59). Clinical features of group A were different to group B: higher mean Karnofsky Performance Status Index 70.3% (95% CI=67.2– 73.5; median=70, CI=60– 80) vs 58.3 (95% CI=53.4– 63.2; median=50, CI=45– 70) (P< 0.001), and mainly group A patients were treated in an ambulatory setting (55.0% group A vs 33.9% group B) (p< 0.001). Both groups had managed BGP with similar mean dosages (group A: 12.0, CI=10.5– 13.4; group B: 13.1, CI=11.0– 15.1) and frequencies of OxyIR/Par alone for group A and in association to other opioids for group B, but Breakthrough cancer Pain (BTcP) exhibited different characteristics in the two groups, showing a lower mean intensity numerical rating scale (NRS) of 7.5 (95% CI=7.2– 7.7; median=7, CI=7– 8 group A) vs 7.9 (95% CI=7.6, 8.2; median= 8, CI=7– 9 group B) (P=0.04) and a higher percentage of patients had a faster onset, defined as the maximum intensity reached in less than 10 minutes, 81.7% (N=98) in group A vs 59.3% (n=35) in group B (P=0.002). Conclusion: This is the first analysis about the efficacy of an immediate-release fixed combination of OxyIR/Par in the real world for moderate-to-severe background cancer pain and breakthrough cancer pain. The oral fixed combination OxyIR/Par provided an adequate level of analgesia for moderate–severe background cancer pain, in a different cohort of cancer patients with different performance status, both in ambulatory and palliative settings. The low dosage of fixed combination OxyIR/Par was effective alone or in association with other opioids. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

44. Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study

Author

Cazzaniga, Marina, primary, Verusio, Claudio, additional, Ciccarese, Mariangela, additional, Fumagalli, Alberto, additional, Sartori, Donata, additional, Valerio, Maria Rosaria, additional, Airoldi, Mario, additional, Moretti, Gabriella, additional, Ficorella, Corrado, additional, Arcangeli, Valentina, additional, Diodati, Lucrezia, additional, Zambelli, Alberto, additional, Febbraro, Antonio, additional, Generali, Daniele, additional, Pistelli, Mirco, additional, Garrone, Ornella, additional, Musolino, Antonino, additional, Vici, Patrizia, additional, Maur, Michela, additional, Mentuccia, Lucia, additional, La Verde, Nicla, additional, Bianchi, Giulia, additional, Artale, Salvatore, additional, Blasi, Livio, additional, Piezzo, Matilde, additional, Atzori, Francesco, additional, Turletti, Anna, additional, Benedetto, Chiara, additional, Cursano, Maria Concetta, additional, Fabi, Alessandra, additional, Gebbia, Vittorio, additional, Schirone, Alessio, additional, Palumbo, Raffaella, additional, Ferzi, Antonella, additional, Frassoldati, Antonio, additional, Scavelli, Claudio, additional, Clivio, Luca, additional, and Torri on behalf of The EVA Study Group, Valter, additional

Published
2018
Full Text
View/download PDF

46. Moving from the CLEOPATRA study to real life: Results from the G.O.N.O. SUPER trial.

Author

Garrone, Ornella, primary, Giarratano, Tommaso, additional, Saggia, Chiara, additional, Bertolini, Ilaria, additional, Beano, Alessandra, additional, Blondeaux, Eva, additional, Riva, Francesca, additional, D'Onofrio, Loretta, additional, Merlini, Laura, additional, Coltelli, Luigi, additional, La Verde, Nicla Maria, additional, Vandone, Anna Maria, additional, Milani, Andrea, additional, Collovà, Elena, additional, Ardito, Raffaele, additional, Airoldi, Mario, additional, De Conciliis, Enrico, additional, Blasi, Livio, additional, Di Maio, Massimo, additional, and Merlano, Marco Carlo, additional

Published
2018
Full Text
View/download PDF

47. Clinical efficacy of nab-paclitaxel in patients with metastatic pancreatic cancer

Author

De Luca,Rossella, Blasi,Livio, Alù,Massimiliano, Gristina,Valerio, Cicero,Giuseppe, De Luca,Rossella, Blasi,Livio, Alù,Massimiliano, Gristina,Valerio, and Cicero,Giuseppe

Abstract

Rossella De Luca,1 Livio Blasi,2 Massimiliano Alù,2 Valerio Gristina,1 Giuseppe Cicero1 1Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy; 2Medical Oncology Unit, ARNAS Hospital Civico, Di Cristina, Benfratelli, Palermo, Italy Purpose: Pancreatic carcinoma is the neoplasia with the major mortality, and main standard treatments in this cancer increase survival but do not lead to complete recovery of the patient. The aim of this study was to evaluate the efficacy of Abraxane® (nab-paclitaxel) in Italian patients with metastatic pancreatic cancer (MPC).Patients and methods: We conducted a retrospective analysis of 80 patients. Overall survival (OS) was the primary end point for evaluating the efficacy of nab-paclitaxel in combination with gemcitabine treatment, while carbohydrate antigen 19-9 (CA 19-9) reduction, safety, progression-free survival (PFS), overall response rate and reduction in pain were secondary end points.Results: The median OS was 8 months, and the median PFS was 5 months. A considerable difference in CA 19-9 before and after treatment was observed. Descriptive and correlation analyses were done to examine the relationship between CA 19-9 response and OS. Linear regression analysis between OS and CA 19-9 response revealed that CA 19-9 is an important predictor of OS, showing a positive correlation.Conclusion: Nab-paclitaxel is a well-tolerated and effective treatment for patients affected by MPC. The drug showed an improved tolerability profile, significant pain relief and an increase in survival rate. Keywords: Abraxane, chemotherapy, pancreatic carcinoma, metastasis, CA 19-9, pain, overall survival

Published
2018

48. Predictive factors for 6 vs 12 cycles of Folfiri-Bevacizumab in metastatic colorectal cancer

Author

Formica, Vincenzo, primary, Ionta, Maria Teresa, additional, Massidda, Bruno, additional, Vessia, Giacomo, additional, Maiorino, Luigi, additional, Casaretti, Rossana, additional, Natale, Donato, additional, Barberis, Giuseppe, additional, Filippelli, Gianfranco, additional, Greco, Ettore, additional, Blasi, Livio, additional, Mancarella, Sergio, additional, Russo, Anna, additional, Barbato, Enrico, additional, Di Lullo, Liberato, additional, and Roselli, Mario, additional

Published
2017
Full Text
View/download PDF

49. Multicenter study of the evaluation of eribulin (E) use in Sicily in metastatic breast cancer (MBC): A prospective registry (VESPRY trial).

Author

Adamo, Vincenzo, primary, Ricciardi, Giuseppina, additional, Giuffrida, Dario, additional, Scandurra, Giuseppa, additional, Russo, Antonio, additional, Blasi, Livio, additional, Spadaro, Pietro, additional, Lucenti, Antonio, additional, Soto Parra, Hector J., additional, Savarino, Antonino, additional, Ferraú, Francesco, additional, Zerilli, Filippo, additional, Verderame, Francesco, additional, Butera, Alfredo, additional, Franchina, Veronica, additional, Cottini, Lorenzo, additional, Fedele, Guido, additional, and Caruso, Michele, additional

Published
2017
Full Text
View/download PDF

50. Prolonged (PI) vs short-term irinotecan (STI) administration: The Martha trial—A SICOG (Southern Italy Cooperative Oncology Group) randomized phase III study in the first-line setting of metastatic colorectal cancer (mCRC) patients (pts).

Author

Formica, Vincenzo, primary, Ionta, Maria Teresa, additional, Giacomo, Vessia, additional, Maiorino, Luigi, additional, Casaretti, Rossana, additional, Natale, Donato, additional, Barberis, Giuseppe, additional, Filippelli, Gianfranco, additional, Greco, Ettore, additional, Blasi, Livio, additional, Mancarella, Sergio, additional, Russo, Anna, additional, Barbato, Enrico, additional, Di Lullo, Liberato, additional, and Roselli, Mario, additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results